Stay updated on T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The website has been updated to version 2.14.1 on January 17, 2025, following the removal of version 2.14.0 on December 20, 2024.
    Difference
    1%
    Check dated 2025-01-19T22:04:02.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The type of intervention has been updated from version v2.13.3 to v2.14.0.
    Difference
    1.0%
    Check dated 2025-01-12T17:33:31.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    A new addition was made on December 20, 2024, while a deletion occurred on November 25, 2024.
    Difference
    0.7%
    Check dated 2024-12-21T23:50:35.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.3%
    Check dated 2024-12-14T22:38:22.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T16:04:36.000Z thumbnail image
  8. Check
    56 days ago
    Change Detected
    Summary
    A new addition was made on November 25, 2024, while previous content was deleted on October 22, 2024.
    Difference
    0.7%
    Check dated 2024-11-30T12:53:04.000Z thumbnail image

Stay in the know with updates to T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.